SAFETY: Stabilization Points to Third Hospital Line Assessment oF the Impact of the usE of Infrascanner Model 2500 to Provide Decision Support for Diagnosis/Screening of Traumatic Brain InjurY in Ukraine
Launched by INFRASCAN, INC. · Jun 2, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial, called SAFETY, is studying a handheld device called the Infrascanner Model 2500, which helps doctors quickly identify traumatic brain injuries, like bleeding in the brain, in patients who have been injured in combat. The goal is to see if using this device can speed up the process of diagnosing these injuries and improve patient care in war zones. The study will take place in various hospitals in Ukraine, where patients showing signs of head trauma will be monitored.
To participate, individuals must have suspected combat-related head injuries, which can be identified by certain signs like a lower level of consciousness, unusual pupil responses, or differences in arm and leg movement. Patients with severe scalp injuries that make it hard to use the Infrascanner will not be eligible. Throughout the trial, participants can expect to receive standard medical care, and their progress will be tracked both before and after the device is introduced to see if it helps doctors diagnose injuries more quickly. This research is important because it aims to improve how brain injuries are detected and treated in challenging environments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with suspected combat-related head trauma identified by clinical signs of TBI on admission to the clinical enrollment site
- * Clinical signs of TBI:
- • Decreased GCS score
- • Abnormal pupil exam
- • Asymmetrical motor exam
- • The presence of pharmacologic sedation is not exclusion criteria.
- Exclusion Criteria:
- • Evidence of extensive scalp injury that prevent proper placement of the Infrascanner device on a subject's head or prevent placement of the device in the specified locations.
- • Extensive scalp injury includes lacerations, avulsions, or abrasions
About Infrascan, Inc.
Infrascan, Inc. is a pioneering clinical trial sponsor dedicated to advancing innovative medical technologies for the rapid assessment and management of traumatic brain injuries (TBIs). With a focus on developing non-invasive diagnostic solutions, Infrascan leverages cutting-edge imaging and monitoring techniques to enhance patient outcomes and streamline clinical decision-making. The company collaborates with healthcare professionals and research institutions to conduct rigorous clinical trials, ensuring the efficacy and safety of its products. Committed to improving patient care and safety, Infrascan aims to transform the landscape of TBI management through scientific excellence and innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Dnipro, , Ukraine
Kyiv, , Ukraine
Vinnytsia, , Ukraine
Patients applied
Trial Officials
Dmytro Dmytriiev, MD, PhD, MBA
Principal Investigator
Vinnytsia City Clinical Hospital named after M.I.Pirogov of Vinnitsya Regional Council
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported